ArticleCancer management and research2025
The Role of Pan-Cytokeratin In Tumor Budding Upgrading In Malignant Colorectal Polyps At Stage pT1.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Tumor budding (TB) is an established prognostic factor in early colorectal cancer. However, its evaluation on hematoxylin-eosin (H&E) slides may underestimate the true budding activity. This study aimed to investigate the role of pan-cytokeratin (Pan-CK) immunohistochemistry in upgrading TB assessment in malignant colorectal polyps at the pT1 stage and to determine clinicopathological factors associated with TB upgrading. Patients and Methods: We retrospectively reviewed 104 malignant colorectal polyps at the pT1 stage diagnosed between January 2015 and June 2024 at the University Medical Center, Ho Chi Minh City. TB was assessed on H&E and Pan-CK stained slides according to the 2016 International Tumor Budding Consensus Conference (ITBCC) criteria. Cases were classified as Bd1 (0-4 buds), Bd2 (5-9 buds), or Bd3 (≥10 buds). Upgrading was defined as an increase in TB grade on Pan-CK compared with H&E, particularly evaluated among cases classified as Bd1 on H&E. Clinicopathological features associated with upgrading were analyzed using univariate and multivariate models. Results: The number of tumor buds was significantly higher on Pan-CK compared with H&E (median [IQR] 1.0 [0.0-7.0] vs 0.5 [0.0-3.0]; p < 0.001). Among 90 cases classified as Bd1 on H&E, 25 (27.78%) were upgraded to Bd2/3 after Pan-CK staining. In univariate analysis, higher Haggitt/Kikuchi level and the presence of synchronous polyps were significantly associated with upgrading, whereas tumor grade 2 demonstrated a borderline association. Multivariate analysis identified synchronous polyps as the only independent predictor (OR = 3.00, 95% CI: 1.03-8.76; p = 0.045). Conclusion: Pan-CK substantially increases TB detection and grading in pT1 malignant colorectal polyps. Synchronous polyps were identified as the sole independent predictor of TB upgrading, representing a novel finding. Selective Pan-CK use in these cases may optimize resources and guide management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.